X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KPI-012 is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially treat persistent corneal epithelial defect (PCED).
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: KPI-012
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
KPI-012 is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially treat persistent corneal epithelial defect (PCED).
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: KPI-012
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, it has the potential to correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases.
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: KPI-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: KPI-012
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Deal Size: $31.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 28, 2022
Details:
KPI-012, is human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors can potentially correct impaired corneal healing that is an underlying etiology of multiple severe ocular diseases.
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: KPI-012
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
The acquisition will complement Alcon’s existing portfolio in the large and fast-growing dry eye category. EYSUVIS (Loteprednol Etabonate) will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Free formulations.
Lead Product(s): Loteprednol Etabonate
Therapeutic Area: Ophthalmology Product Name: Eysuvis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: Undisclosed Upfront Cash: $60.0 million
Deal Type: Acquisition May 23, 2022
Details:
Data for CMB-012 (KPI-012), demonstrated rapid and complete wound healing, with six of eight (75%) patients achieving complete healing within four weeks; all remained healed through end of follow-up.
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: CMB-012
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2022
Details:
KPI-012, a novel investigational secretome therapy, initially targeting persistent corneal epithelial defects and multiple proprietary new chemical entity preclinical development programs targeted to address unmet medical needs, including both front and back of eye diseases.
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: CMB-012
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
The acquisition accelerate strengthening of Kala’s pipeline for the treatment of the eye diseases by including Combangio's CMB-012, a novel secretome therapy, now known as KPI-012, for the complex wound healing process in persistent corneal epithelial defect (PCED).
Lead Product(s): KPI-012
Therapeutic Area: Ophthalmology Product Name: CMB-012
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kala Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2021
Details:
Kala is marketing two approved ophthalmology products, EYSUVIS® for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (“DED”), and INVELTYS® for the treatment of post-operative inflammation and pain following ocular surgery.
Lead Product(s): Loteprednol Etabonate
Therapeutic Area: Ophthalmology Product Name: Eysuvis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
